Researchers discover toxin that kills bacteria in unprecedented ways
McMaster researchers have discovered a previously unknown bacteria-killing toxin that could pave the way for a new generation of antibiotics.
The study, led by John Whitney at the Michael G. DeGroote Institute for Infectious Disease Research, shows that the bacterial pathogen Pseudomonas aeruginosa, known to cause hospital-acquired infections such as pneumonia, secretes a toxin that has evolved to kill other species of bacteria.
For Whitney, the key aspect of his discovery is not just that this toxin kills bacteria, but how it does so.
“This research is significant, because it shows that the toxin targets essential RNA molecules of other bacteria, effectively rendering them non-functional,” says Whitney, an associate professor in the department of biochemistry and biomedical sciences.
“Like humans, bacteria require properly functioning RNA in order to live.”
First study author Nathan Bullen, a graduate student in biochemistry and biomedical sciences, describes it as “a total assault on the cell” because of the number of essential pathways depend on functional RNAs.
Whitney and Bullen, together with colleagues at Imperial College London and the University of Manitoba, have studied this toxin for nearly three years to understand exactly how it functions at a molecular level.
The breakthrough, published in the journal Molecular Cell, was achieved by Bullen after rigorous experimentation on common targets of toxins, such as protein and DNA molecules, before eventually testing the toxin against RNA.
This discovery breaks well-established precedents set by protein-targeting toxins secreted by other bacteria, such as those that cause cholera and diphtheria.
Researchers say that this development holds great potential for future research that could eventually lead to new innovations that combat infection-causing bacteria.
Whitney says future antibiotic development can build on the newly discovered vulnerability.
This article was republished with permission from the Institute for Infectious Disease Research at McMaster University. Read the original.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Novel inhibitor targets RAS-driven cancers
Researchers in Louisville identify a small-molecule drug that blocks RALGEF signaling downstream of mutant RAS. The compound suppresses tumor growth with low toxicity, revealing a new therapeutic strategy for RAS-driven malignancies.

Catching tau in the act
Using a new proximity-labeling approach, researchers reveal how tangles of the brain-associated protein tau may disrupt RNA biology long before neurons die.

How copper delivery fuels bacterial respiration
Researchers identify the roles of several proteins in copper homeostasis in the aerobic bacterium Caulobacter vibrioides.

Revealing the glycoproteome of a cancer subtype
Researchers mapped the glycoproteome of extrahepatic cholangiocarcinoma and compared it to intrahepatic tumors. Differences in sugar modifications and immune cell content suggest new biomarkers and guide development of targeted immunotherapies.

Uncovering the mechanisms of a glycosylation disorder
Mutations in OGT, an enzyme that adds sugars to proteins, cause a rare neurological disorder. Using proteomics, researchers reveal how OGT interactions with TET proteins may trigger epigenetic changes and early neural defects.

Heat shock proteins as a promising breast cancer therapeutic
Researchers unveiled isoform-specific targets on heat shock protein 90 which may be beneficial in therapeutic development.